1. Home
  2. Analysis
  3. Uloric
  4. Krystexxa

Uloric and Krystexxa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Uloric (febuxostat) and Krystexxa (pegloticase). Common drug interactions include abasia among females and therapeutic response decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Uloric and Krystexxa. It is created by eHealthMe based on reports of 66 people who take the same drugs from the FDA, and is updated regularly.

What is Uloric?

Uloric has active ingredients of febuxostat. It is often used in gout. eHealthMe is studying from 8,067 Uloric users. Check the latest studies of Uloric.

What is Krystexxa?

Krystexxa has active ingredients of pegloticase. eHealthMe is studying from 2,548 Krystexxa users. Check the latest studies of Krystexxa.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 23, 2026

66 people who take Uloric and Krystexxa together, and have interactions are studied.

Uloric and Krystexxa drug interactions.

What are the common drug interactions of Uloric and Krystexxa, by gender? *:

female:

  1. Abasia (inability to walk)
  2. Adrenal disorder
  3. Anuria (failure of the kidneys to produce urine)
  4. Infusion related reaction
  5. Pain
  6. Renal failure (kidney dysfunction)
  7. Therapeutic response decreased (less preventive response)
  8. Blood uric acid increased
  9. Lymphoedema (localized fluid retention and tissue swelling)

male:

  1. Therapeutic response decreased (less preventive response)
  2. Infusion related reaction
  3. Somnolence (a state of near-sleep, a strong desire for sleep)
  4. Blood glucose increased
  5. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  6. Platelet count increased
  7. Rash
  8. Therapeutic response unexpected
  9. Abasia (inability to walk)
  10. Diarrhoea

What are the common drug interactions of Uloric and Krystexxa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Infusion related reaction
  2. Therapeutic response decreased (less preventive response)
  3. Hypersensitivity

30-39:

  1. Therapeutic response decreased (less preventive response)
  2. Infusion related reaction
  3. Rash
  4. Drug ineffective
  5. Pulmonary embolism (blockage of the main artery of the lung)

40-49:

  1. Therapeutic response decreased (less preventive response)
  2. Infusion related reaction
  3. Anaphylactic reaction (serious allergic reaction)
  4. Blood glucose increased
  5. Haematocrit decreased
  6. Haemoglobin decreased
  7. Platelet count increased
  8. Fatigue (feeling of tiredness)
  9. Asthenia (weakness)
  10. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)

50-59:

  1. Therapeutic response decreased (less preventive response)
  2. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  3. Haematocrit decreased
  4. Haemoglobin decreased
  5. Therapeutic response unexpected
  6. Infusion related reaction
  7. Contusion (a type of hematoma of tissue in which capillaries)
  8. Fall

60+:

  1. Nausea (feeling of having an urge to vomit)
  2. Dizziness
  3. Pain
  4. Renal failure (kidney dysfunction)
  5. Therapeutic response decreased (less preventive response)
  6. Diarrhoea
  7. Malaise (a feeling of general discomfort or uneasiness)
  8. Methaemoglobinaemia (a disorder characterized by the presence of a higher than normal level of methemoglobin in blood)
  9. Weight decreased
  10. Weight increased

What are the existing conditions these people have? *

  1. Gouty Tophus (a deposit of urates in the skin and tissue around a joint or in the external ear): 15 people, 22.73%
  2. Allergies: 10 people, 15.15%
  3. High Blood Pressure: 6 people, 9.09%
  4. Pain: 5 people, 7.58%

* Approximation only. Some reports may have incomplete information.

Do you take Uloric and Krystexxa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Uloric and Krystexxa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Uloric:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Krystexxa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Uloric and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Krystexxa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on febuxostat and pegloticase (the active ingredients of Uloric and Krystexxa, respectively), and Uloric and Krystexxa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.